Dengue Antibodies, then Zika: A Fatal Sequence in Mice Jonathan J. Miner, Michael S. Diamond  Immunity  Volume 46, Issue 5, Pages 771-773 (May 2017) DOI: 10.1016/j.immuni.2017.04.023 Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 1 Antibody-Dependent Enhancement of ZIKV Infection Bardina et al. injected Stat2−/− immunodeficient mice with DENV- or WNV-immune plasma and subsequently inoculated them with ZIKV. The cross-reactive antibodies against WNV and DENV promoted enhanced ZIKV replication, likely in myeloid cells expressing Fc-γRs; this resulted in higher viral burden in different tissues, greater weight loss, and increased lethality. However, ADE of ZIKV infection has yet to be demonstrated in experimental or epidemiological studies in non-human primates and humans, respectively. If ADE does occur in humans, it might explain the increased incidence of severe clinical manifestations of ZIKV infection, including congenital malformations and Guillain-Barré syndrome, that has been observed in the recent epidemic in areas with high rates of prior flavivirus infection and immunity. Immunity 2017 46, 771-773DOI: (10.1016/j.immuni.2017.04.023) Copyright © 2017 Elsevier Inc. Terms and Conditions